Integrative Analysis of a Novel Immunogenic PANoptosis‑related Gene Signature in Diffuse Large B-cell Lymphoma for Prognostication and Therapeutic Decision-making

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 5

PMID 39639038

Authors

Ming Xu

Ming Ruan

Wenhua Zhu

Jiayue Xu

Ling Lin

Weili Li

Weirong Zhu

Affiliations

Soon will be listed here.

Abstract

This study aimed to develop a PANoptosis-related gene prognostic index (PANGPI) to explore its potential value in predicting the prognosis and immunotherapy response of diffuse large B-cell lymphoma (DLBCL). Differentially expressed genes of DLBCL from GEO databases were analyzed and mapped to the PANoptosis gene set. The independent prognostic value of the PANGPI signature was evaluated using LASSO Cox regression and multivariate Cox regression. Additionally, the tumor infiltrating lymphocyte (TIL) characteristics and mutation landscape of both subgroups were evaluated, and drug sensitivity was predicted using the GDSC database. Furthermore, in silico docking and molecular dynamic simulation studies were presented to elucidate the mode of interaction of these predicted drugs. The PANGPI risk score was an independent risk factor for the prognosis of patients with DLBCL and exhibited good prognostic predictive performance. Furthermore, the cytolytic activity of the TILs was positively correlated with the PANGPI scores. Additionally, the PANGPI enabled the identification of 3 chemotherapeutic agents, including BMS-536924, Gefitinib, Navitoclax for DLBCL patients in the high-risk group. We established a novel PANoptosis-related gene subtyping system in DLBCL, which could shed a novel light on the development of new biomarkers for DLBCL.

References

Soman S, Sivakumar K, Sreekumar E . Molecular dynamics simulation studies and in vitro site directed mutagenesis of avian beta-defensin Apl_AvBD2. BMC Bioinformatics. 2010; 11 Suppl 1:S7. PMC: 3009542. DOI: 10.1186/1471-2105-11-S1-S7. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Ren X, Guo S, Guan X, Kang Y, Liu J, Yang X . Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy. Front Immunol. 2022; 13:790113. PMC: 8918549. DOI: 10.3389/fimmu.2022.790113. View

Zheng Y, Li J, Liu B, Xie Z, He Y, Xue D . Global trends in PANoptosis research: bibliometrics and knowledge graph analysis. Apoptosis. 2023; 29(1-2):229-242. DOI: 10.1007/s10495-023-01889-3. View

Wei Y, Lan C, Yang C, Liao X, Zhou X, Huang X . Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response. Sci Rep. 2023; 13(1):14519. PMC: 10477271. DOI: 10.1038/s41598-023-41670-9. View

Wang J, Wang Y, Wan L, Chen X, Zhang H, Yang S . Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma. Front Immunol. 2023; 14:1230017. PMC: 10542897. DOI: 10.3389/fimmu.2023.1230017. View

Smardz P, Anila M, Rogowski P, Li M, Rozycki B, Krupa P . A Practical Guide to All-Atom and Coarse-Grained Molecular Dynamics Simulations Using Amber and Gromacs: A Case Study of Disulfide-Bond Impact on the Intrinsically Disordered Amyloid Beta. Int J Mol Sci. 2024; 25(12). PMC: 11204378. DOI: 10.3390/ijms25126698. View

Kruse B, Buzzai A, Shridhar N, Braun A, Gellert S, Knauth K . CD4 T cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023; 618(7967):1033-1040. PMC: 10307640. DOI: 10.1038/s41586-023-06199-x. View

Fekete J, Gyorffy B . A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines. Comput Struct Biotechnol J. 2022; 20:2885-2894. PMC: 9198269. DOI: 10.1016/j.csbj.2022.06.007. View

10.

Hua J, Wang X, Ma L, Li J, Cao G, Zhang S . CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. Mol Cancer. 2022; 21(1):123. PMC: 9172052. DOI: 10.1186/s12943-022-01595-9. View

11.

He M, Kridel R . Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021; 35(8):2151-2165. DOI: 10.1038/s41375-021-01285-3. View

12.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

13.

Sundaram B, Pandian N, Mall R, Wang Y, Sarkar R, Kim H . NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023; 186(13):2783-2801.e20. PMC: 10330523. DOI: 10.1016/j.cell.2023.05.005. View

14.

Gheidari D, Mehrdad M, Hoseini F . Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPK inhibitors. Front Pharmacol. 2024; 15:1360226. PMC: 11253198. DOI: 10.3389/fphar.2024.1360226. View

15.

Zhang J, Guo Y, Fang H, Guo X, Zhao L . Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment. Autoimmunity. 2023; 56(1):2259126. DOI: 10.1080/08916934.2023.2259126. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Lee S, Karki R, Wang Y, Nguyen L, Kalathur R, Kanneganti T . AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021; 597(7876):415-419. PMC: 8603942. DOI: 10.1038/s41586-021-03875-8. View

18.

Blanco J, Porto-Pazos A, Pazos A, Fernandez-Lozano C . Prediction of high anti-angiogenic activity peptides in silico using a generalized linear model and feature selection. Sci Rep. 2018; 8(1):15688. PMC: 6200741. DOI: 10.1038/s41598-018-33911-z. View

19.

Yi M, Niu M, Xu L, Luo S, Wu K . Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021; 14(1):10. PMC: 7792099. DOI: 10.1186/s13045-020-01027-5. View

20.

Christgen S, Zheng M, Kesavardhana S, Karki R, Malireddi R, Banoth B . Identification of the PANoptosome: A Molecular Platform Triggering Pyroptosis, Apoptosis, and Necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020; 10:237. PMC: 7274033. DOI: 10.3389/fcimb.2020.00237. View